185 related articles for article (PubMed ID: 33848635)
1. Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice.
Janssens J; Hermans B; Vandermeeren M; Barale-Thomas E; Borgers M; Willems R; Meulders G; Wintmolders C; Van den Bulck D; Bottelbergs A; Ver Donck L; Larsen P; Moechars D; Edwards W; Mercken M; Van Broeck B
Neurobiol Dis; 2021 Jul; 154():105365. PubMed ID: 33848635
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.
Jacobsen H; Ozmen L; Caruso A; Narquizian R; Hilpert H; Jacobsen B; Terwel D; Tanghe A; Bohrmann B
J Neurosci; 2014 Aug; 34(35):11621-30. PubMed ID: 25164658
[TBL] [Abstract][Full Text] [Related]
3. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
4. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
Hook G; Yu J; Toneff T; Kindy M; Hook V
J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
[TBL] [Abstract][Full Text] [Related]
5. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.
Peters F; Salihoglu H; Rodrigues E; Herzog E; Blume T; Filser S; Dorostkar M; Shimshek DR; Brose N; Neumann U; Herms J
Acta Neuropathol; 2018 May; 135(5):695-710. PubMed ID: 29327084
[TBL] [Abstract][Full Text] [Related]
6. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.
Eketjäll S; Janson J; Jeppsson F; Svanhagen A; Kolmodin K; Gustavsson S; Radesäter AC; Eliason K; Briem S; Appelkvist P; Niva C; Berg AL; Karlström S; Swahn BM; Fälting J
J Neurosci; 2013 Jun; 33(24):10075-84. PubMed ID: 23761903
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
[TBL] [Abstract][Full Text] [Related]
8. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
Read J; Suphioglu C
Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
[TBL] [Abstract][Full Text] [Related]
9. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation.
Brendel M; Jaworska A; Overhoff F; Blume T; Probst F; Gildehaus FJ; Bartenstein P; Haass C; Bohrmann B; Herms J; Willem M; Rominger A
Theranostics; 2018; 8(18):4957-4968. PubMed ID: 30429879
[TBL] [Abstract][Full Text] [Related]
11. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
12. BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology.
Cai Y; Zhang XM; Macklin LN; Cai H; Luo XG; Oddo S; Laferla FM; Struble RG; Rose GM; Patrylo PR; Yan XX
Neurotox Res; 2012 Feb; 21(2):160-74. PubMed ID: 21725719
[TBL] [Abstract][Full Text] [Related]
13. Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.
Dorresteijn B; Rotman M; Faber D; Schravesande R; Suidgeest E; van der Weerd L; van der Maarel SM; Verrips CT; El Khattabi M
FEBS J; 2015 Sep; 282(18):3618-31. PubMed ID: 26147692
[TBL] [Abstract][Full Text] [Related]
14. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
[TBL] [Abstract][Full Text] [Related]
15. Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.
Thakker DR; Sankaranarayanan S; Weatherspoon MR; Harrison J; Pierdomenico M; Heisel JM; Thompson LA; Haskell R; Grace JE; Taylor SJ; Albright CF; Shafer LL
J Neurosci; 2015 Apr; 35(17):6931-6. PubMed ID: 25926467
[TBL] [Abstract][Full Text] [Related]
16. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy.
Wang A; Das P; Switzer RC; Golde TE; Jankowsky JL
J Neurosci; 2011 Mar; 31(11):4124-36. PubMed ID: 21411653
[TBL] [Abstract][Full Text] [Related]
17. Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo.
Kim ML; Zhang B; Mills IP; Milla ME; Brunden KR; Lee VM
J Neurosci; 2008 Nov; 28(46):12052-61. PubMed ID: 19005070
[TBL] [Abstract][Full Text] [Related]
18. Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.
Frost JL; Liu B; Kleinschmidt M; Schilling S; Demuth HU; Lemere CA
Neurodegener Dis; 2012; 10(1-4):265-70. PubMed ID: 22343072
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease.
Devi L; Ohno M
Transl Psychiatry; 2013 Jul; 3(7):e284. PubMed ID: 23880880
[TBL] [Abstract][Full Text] [Related]
20. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
Imbimbo BP; Watling M
Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
[No Abstract] [Full Text] [Related]
[Next] [New Search]
